BBR Partners LLC lifted its stake in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 620.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 180,000 shares of the company's stock after purchasing an additional 155,000 shares during the quarter. BBR Partners LLC owned about 0.35% of 2seventy bio worth $850,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. SkyView Investment Advisors LLC grew its stake in shares of 2seventy bio by 25.0% in the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company's stock valued at $48,000 after buying an additional 2,500 shares during the period. GSA Capital Partners LLP purchased a new position in 2seventy bio in the third quarter worth approximately $64,000. Nisa Investment Advisors LLC purchased a new position in 2seventy bio in the second quarter worth approximately $52,000. Intech Investment Management LLC acquired a new stake in 2seventy bio during the third quarter worth $69,000. Finally, SG Americas Securities LLC purchased a new stake in 2seventy bio in the third quarter valued at $80,000. Hedge funds and other institutional investors own 93.90% of the company's stock.
2seventy bio Stock Performance
Shares of 2seventy bio stock traded up $0.27 during trading hours on Thursday, hitting $3.96. The company's stock had a trading volume of 208,245 shares, compared to its average volume of 746,002. The firm has a fifty day moving average of $4.53 and a 200-day moving average of $4.43. The stock has a market cap of $204.30 million, a price-to-earnings ratio of -2.13 and a beta of 1.78. 2seventy bio, Inc. has a twelve month low of $1.67 and a twelve month high of $6.40.
About 2seventy bio
(
Free Report)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
See Also
Before you consider 2seventy bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 2seventy bio wasn't on the list.
While 2seventy bio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
